keyword
MENU ▼
Read by QxMD icon Read
search

Ferric carboxymaltose

keyword
https://www.readbyqxmd.com/read/27915456/use-of-iron-sucrose-and-red-blood-cell-transfusions-in-anaemic-cancer-patients-in-france-oncofer-study
#1
Elisabeth Luporsi, Alain Toledano, Dominique Spaeth, Florian Scotté, Marc Espié, Stéphanie Perot, Ladan Duvillié, Isabelle Pithois Merli, Roland Bugat
PURPOSE: This report describes the results of an observational, retrospective cohort study, evaluating the use of iron sucrose (IS) and red blood cell (RBC) transfusions in patients with cancer in routine clinical practice in France. A parallel investigated cohort treated with ferric carboxymaltose (FCM) has been reported earlier. METHODS: Data of patients with a solid tumour or haematological malignancy who have received IS or an RBC transfusion during 2010 from 3 months prior (M-3) to 3 months post first treatment (M+3) were analysed...
December 3, 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27907058/choice-of-high-dose-intravenous-iron-preparation-determines-hypophosphatemia-risk
#2
Benedikt Schaefer, Philipp Würtinger, Armin Finkenstedt, Vickie Braithwaite, André Viveiros, Maria Effenberger, Irene Sulzbacher, Alexander Moschen, Andrea Griesmacher, Herbert Tilg, Wolfgang Vogel, Heinz Zoller
BACKGROUND: Ferric carboxymaltose (FCM) and iron isomaltoside 1000 (IIM) are increasingly used because they allow correction of severe iron deficiency in a single infusion. A transient decrease in serum phosphate concentrations is a frequent side effect of FCM. AIM: To characterize this adverse event and search for its predictors in a gastroenterology clinic patient cohort. METHODS: Electronic medical records of patients attending the University Hospital of Innsbruck were searched for the keywords ferric carboxymaltose or iron isomaltoside...
2016: PloS One
https://www.readbyqxmd.com/read/27889746/distinct-in-vitro-complement-activation-by-various-intravenous-iron-preparations
#3
Julia Cordelia Hempel, Felix Poppelaars, Mariana Gaya da Costa, Casper F M Franssen, Thomas P G de Vlaam, Mohamed R Daha, Stefan P Berger, Marc A J Seelen, Carlo A J M Gaillard
BACKGROUND: Intravenous (IV) iron preparations are widely used in the treatment of anemia in patients undergoing hemodialysis (HD). All IV iron preparations carry a risk of causing hypersensitivity reactions. However, the pathophysiological mechanism is poorly understood. We hypothesize that a relevant number of these reactions are mediated by complement activation, resulting in a pseudo-anaphylactic clinical picture known as complement activation-related pseudo allergy (CARPA). METHODS: First, the in-vitro complement-activating capacity was determined for 5 commonly used IV iron preparations using functional complement assays for the 3 pathways...
November 26, 2016: American Journal of Nephrology
https://www.readbyqxmd.com/read/27859495/drug-specific-hypophosphatemia-and-hypersensitivity-reactions-following-different-intravenous-iron-infusions
#4
Palle Bager, Christian L Hvas, Jens F Dahlerup
AIMS: Intravenous (IV) iron infusions have been associated with hypophosphatemia (HP) and hypersensitivity reactions (HSRs). No studies have compared the side effects of ferric carboxymaltose (FCM) with those of isomaltoside 1000 (ISM). This study aimed to describe the occurrence of HP and HSRs following the administration of either FCM or ISM. METHODS: Data on 231outpatients treated with IV iron infusions, between November 2011 and April 2014, were collected. During that period, the department made a switch from FCM to ISM and then back to FCM...
November 17, 2016: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27856776/practice-guideline-summary-treatment-of-restless-legs-syndrome-in-adults-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology
#5
John W Winkelman, Melissa J Armstrong, Richard P Allen, K Ray Chaudhuri, William Ondo, Claudia Trenkwalder, Phyllis C Zee, Gary S Gronseth, David Gloss, Theresa Zesiewicz
OBJECTIVE: To make evidence-based recommendations regarding restless legs syndrome (RLS) management in adults. METHODS: Articles were classified per the 2004 American Academy of Neurology evidence rating scheme. Recommendations were tied to evidence strength. RESULTS AND RECOMMENDATIONS: In moderate to severe primary RLS, clinicians should consider prescribing medication to reduce RLS symptoms. Strong evidence supports pramipexole, rotigotine, cabergoline, and gabapentin enacarbil use (Level A); moderate evidence supports ropinirole, pregabalin, and IV ferric carboxymaltose use (Level B)...
November 16, 2016: Neurology
https://www.readbyqxmd.com/read/27852236/effects-of-intravenous-iron-on-fibroblast-growth-factor-23-fgf23-in-haemodialysis-patients-a-randomized-controlled-trial
#6
Matthew A Roberts, Louis Huang, Darren Lee, Robert MacGinley, Stefanie M A Troster, Annette B Kent, Sukhvinder S Bansal, Iain C Macdougall, Lawrence P McMahon
BACKGROUND: Intravenous iron affects serum levels of intact fibroblast growth factor-23 (iFGF23) and its cleavage product c-terminal FGF23 (cFGF23) in iron-deficient people with normal renal function. We hypothesized that intravenous iron modulates iFGF23 and cFGF23 in haemodialysis patients differently according to the type of iron used. METHODS: Prevalent, stable haemodialysis patients requiring protocol-based intravenous iron therapy were randomized to a single 200 mg dose of either ferric carboxymaltose (FCM) or iron sucrose (IS)...
November 16, 2016: BMC Nephrology
https://www.readbyqxmd.com/read/27823710/clinical-efficacy-of-ferric-carboxymaltose-treatment-in-patients-with-restless-legs-syndrome
#7
Yong Won Cho, Richard P Allen, Christopher J Earley
OBJECTIVE: There have been three randomized, placebo-controlled, double-blind studies of intravenous iron in restless legs syndrome (RLS), with differing outcomes. The one positive study used ferric carboxymaltose (FCM) at a total dose of 1000 mg. The purpose of this study was to replicate and extend the findings from the prior FCM study. METHODS: Non-anemic, idiopathic RLS patients were enrolled in a randomized, double-blinded, placebo-controlled study and received either 1000 mg FCM or placebo as a single infusion (phase I)...
September 2016: Sleep Medicine
https://www.readbyqxmd.com/read/27793204/high-dose-intravenously-administered-iron-versus-orally-administered-iron-in-blood-donors-with-iron-deficiency-study-protocol-for-a-randomised-controlled-trial
#8
Susanne Macher, Camilla Drexler, Ines Lindenau, Nazanin Sareban, Peter Schlenke, Karin Amrein
BACKGROUND: About 2-3 % of the population participates in blood donation programmes. Each whole blood donation or ten apheresis donations cause a loss of 200-250 mg of iron. As a result, one of the most common risks of regular blood donors is iron deficiency. Although this has been known for decades, in most countries, iron status is currently not assessed or treated in this population. Premenopausal women are particularly affected, as they have lower iron reserves and higher daily requirements...
October 28, 2016: Trials
https://www.readbyqxmd.com/read/27776750/intravenous-ferric-carboxymaltose-in-children-with-iron-deficiency-anemia-who-respond-poorly-to-oral-iron
#9
Jacquelyn M Powers, Mark Shamoun, Timothy L McCavit, Leah Adix, George R Buchanan
OBJECTIVE: To assess the benefits and risks of intravenous (IV) ferric carboxymaltose (FCM) in children with iron deficiency anemia (IDA). STUDY DESIGN: In a retrospective cohort study of patients seen at our center, we identified all FCM infusions in children with IDA over a 12-month period through a query of pharmacy records. Clinical data, including hematologic response and adverse effects, were extracted from the electronic medical record. RESULTS: A total of 116 IV FCM infusions were administered to 72 patients with IDA refractory to oral iron treatment (median age, 13...
October 21, 2016: Journal of Pediatrics
https://www.readbyqxmd.com/read/27774269/rationale-and-design-of-a-pilot-randomized-controlled-trial-to-assess-the-role-of-intravenous-ferric-carboxymaltose-in-asian-patients-with-heart-failure-practice-asia-hf
#10
Tee Joo Yeo, Poh Shuan Daniel Yeo, Farid Abdul Hadi, Timothy Cushway, Kim Yee Lee, Bee Choo Tai, Carolyn S P Lam
AIMS: Iron deficiency (ID) is highly prevalent in patients with heart failure (HF) worldwide regardless of haemoglobin levels. Results from therapeutic trials of intermittently dosed intravenous (i.v.) iron are promising in the ambulatory Caucasian population with HF with reduced left ventricular ejection fraction, although evidence is scarce in Asia. The Pilot Randomized Controlled Trial to Assess the Role of Intravenous Ferric Carboxymaltose in Asian Patients with Heart Failure aims to assess the effect of single-dose i...
June 2016: ESC Heart Failure
https://www.readbyqxmd.com/read/27769970/evolving-therapies-for-the-management-of-chronic-and-acute-decompensated-heart-failure
#11
Jennifer C Cook, Richard H Tran, J Herbert Patterson, Jo E Rodgers
PURPOSE: The pharmacology, clinical efficacy, and safety profiles of evolving therapies for the management of chronic heart failure (HF) and acute decompensated heart failure (ADHF) are described. SUMMARY: HF confers a significant financial burden despite the widespread use of traditional guideline-directed medical therapies such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, β-blockers, and aldosterone receptor antagonists, and the rates of HF-related mortality and hospitalization have remained unacceptably high...
November 1, 2016: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/27679067/the-efficacy-of-iv-ferric-carboxymaltose-in-the-perioperative-management-of-moderate-to-severe-iron-deficiency-anemia
#12
J A Nores
No abstract text is available yet for this article.
November 2015: Journal of Minimally Invasive Gynecology
https://www.readbyqxmd.com/read/27600706/ferric-carboxymaltose-reduces-the-number-of-red-blood-cell-units-transfused-and-allows-transfusion-independence-to-be-obtained-in-patients-with-iron-deficiency-anemia-secondary-to-gastrointestinal-chronic-blood-loss
#13
Ugo Salvadori, Marco Sandri, Cristina Melli, Francesca Polese, Maria Simeoni, Stefano Capelli, Ahmad Al-Khaffaf
BACKGROUND: The aim of this study was to evaluate the effectiveness of ferric carboxymaltose (FCM) in patients with iron deficiency anemia (IDA) secondary to gastrointestinal chronic blood loss (CBL), who received chronic transfusion support. STUDY DESIGN AND METHODS: We retrospectively evaluated 38 patients with IDA (hemoglobin [Hb] < 10 g/dL and ferritin < 12 ng/mL or transferrin saturation [TSAT] < 16%) refractory or intolerant to oral iron therapy that necessitated transfusion support in the previous 12 months...
September 7, 2016: Transfusion
https://www.readbyqxmd.com/read/27592046/acute-decompensated-heart-failure-adhf-a-comprehensive-contemporary-review-on-preventing-early-readmissions-and-postdischarge-death
#14
Bruno M L Rocha, Luiz Menezes Falcão
Heart failure (HF) is an increasingly prevalent syndrome and a leading cause of both first hospitalization and readmissions. Strikingly, up to 25% of the patients are readmitted within 30 to 60-days, accounting for HF as the primary cause for readmission in the adult population. Given its poor prognosis, one could describe it as a "malignant condition". Acute decompensation is intrinsically related to increased right heart tele-diastolic pressures and often related to congestive symptoms. In-hospital strategies to adequately compensate and timely discharge patients are limited...
November 15, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27577248/-iron-deficiency-fatigue-and-restless-legs-syndrome
#15
Bettina Wurzinger, Peter König
Iron deficiency without anaemia is a widespread health problem that often remains undetected. In this context, neurological and psychopathological problems like fatigue and poor concentration are a major issue, but also in Restless-Legs-Syndrome (RLS) iron deficiency is a key element.The exact pathogenesis is often unknown, however, it is known that iron is involved in several very important metabolic processes in the human body. In particular when it comes to fatigue and RLS, it's assumed that reduced activity of tyrosine hydroxylase - a central iron-dependent element of dopamine synthesis - can lead to deficiencies...
October 2016: Wiener Medizinische Wochenschrift
https://www.readbyqxmd.com/read/27576956/pediatric-crohn-s-disease-iron-deficiency-anemia-and-intravenous-iron-treatment-a-follow-up-study
#16
Sara Valério de Azevedo, Catarina Maltez, Ana Isabel Lopes
BACKGROUND AND AIMS: Increasing evidence in adults demonstrates efficacy and safety of IV iron in inflammatory Bowel disease (IBD) associated iron deficiency anemia; however, evidence in pediatric patients is yet scarce and no previous study has included a long follow-up. This study aimed to evaluate safety and efficacy of IV iron (primary end point), and the need of re-treatment (secondary end point), in this setting. METHODS: Prospective recruitment (40 months); PCDAI determined before and after treatment; anemia defined according to WHO criteria; IV iron treatment included iron sucrose and ferric carboxymaltose...
August 31, 2016: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/27570088/intravenous-ferric-carboxymaltose-versus-standard-care-in-the-management-of-postoperative-anaemia-a-prospective-open-label-randomised-controlled-trial
#17
Alhossain A Khalafallah, Carl Yan, Raghad Al-Badri, Ella Robinson, Brooke E Kirkby, Emily Ingram, Zara Gray, Vinod Khelgi, Iain K Robertson, Brian P Kirkby
BACKGROUND: Despite increasing efforts in perioperative management, postoperative iron deficiency anaemia persists, and few data are available about the management of this condition. In this study, we aimed to determine whether giving postoperative intravenous iron (in the form of ferric carboxymaltose) improved iron stores, haemoglobin concentrations, and outcomes following surgery. METHODS: We did a prospective, open-label, randomised, controlled study of patients at two centres (a general hospital and a private health-care centre) in Tasmania, Australia, undergoing elective surgery with functional iron deficiency anaemia (haemoglobin 70-120 g/L and ferritin ≤100 μg/L or iron saturation ≤20%), measured at day 1 postoperatively...
September 2016: Lancet Haematology
https://www.readbyqxmd.com/read/27545647/iron-regulatory-proteins-secure-iron-availability-in-cardiomyocytes-to-prevent-heart-failure
#18
Saba Haddad, Yong Wang, Bruno Galy, Mortimer Korf-Klingebiel, Valentin Hirsch, Abdul M Baru, Fatemeh Rostami, Marc R Reboll, Jörg Heineke, Ulrich Flögel, Stephanie Groos, André Renner, Karl Toischer, Fabian Zimmermann, Stefan Engeli, Jens Jordan, Johann Bauersachs, Matthias W Hentze, Kai C Wollert, Tibor Kempf
AIMS: Iron deficiency (ID) is associated with adverse outcomes in heart failure (HF) but the underlying mechanisms are incompletely understood. Intracellular iron availability is secured by two mRNA-binding iron-regulatory proteins (IRPs), IRP1 and IRP2. We generated mice with a cardiomyocyte-targeted deletion of Irp1 and Irp2 to explore the functional implications of ID in the heart independent of systemic ID and anaemia. METHODS AND RESULTS: Iron content in cardiomyocytes was reduced in Irp-targeted mice...
August 21, 2016: European Heart Journal
https://www.readbyqxmd.com/read/27455240/assessment-of-dextran-antigenicity-of-intravenous-iron-preparations-with-enzyme-linked-immunosorbent-assay-elisa
#19
Susann Neiser, Taija S Koskenkorva, Katrin Schwarz, Maria Wilhelm, Susanna Burckhardt
Intravenous iron preparations are typically classified as non-dextran-based or dextran/dextran-based complexes. The carbohydrate shell for each of these preparations is unique and is key in determining the various physicochemical properties, the metabolic pathway, and the immunogenicity of the iron-carbohydrate complex. As intravenous dextran can cause severe, antibody-mediated dextran-induced anaphylactic reactions (DIAR), the purpose of this study was to explore the potential of various intravenous iron preparations, non-dextran-based or dextran/dextran-based, to induce these reactions...
2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27445502/iron-deficiency-intravenous-substitution-in-a-swiss-academic-primary-care-division-analysis-of-practices
#20
Monica Varcher, Sofia Zisimopoulou, Olivia Braillard, Bernard Favrat, Noëlle Junod Perron
BACKGROUND: Iron deficiency is a common problem in primary care and is usually treated with oral iron substitution. With the recent simplification of intravenous (IV) iron administration (ferric carboxymaltose) and its approval in many countries for iron deficiency, physicians may be inclined to overutilize it as a first-line substitution. OBJECTIVE: The aim of this study was to evaluate iron deficiency management and substitution practices in an academic primary care division 5 years after ferric carboxymaltose was approved for treatment of iron deficiency in Switzerland...
2016: International Journal of General Medicine
keyword
keyword
11331
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"